Antibody Drug Conjugates ADCs

Antibody-drug conjugates come to the fore

Read more

The linker matters in antibody-drug conjugates

Read more

The US continues to lead in oncology approvals

Read more

Revisiting antibody-drug conjugates

Read more

Targeting new medicines at Roche

Read more

The inventive step: antibody-drug conjugates

Read more

Antibodies and ADCs lead cancer pipeline

Read more

ADCs propelled back into the oncology spotlight

Read more

Why Oxford BioTherapeutics is targeting ADCs

Read more

How developers approach antibody drug conjugates

Read more